KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3327.57%.

  • Recursion Pharmaceuticals' EBIT Margin fell 29504800.0% to 3327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 1656.17%, marking a year-over-year decrease of 10514700.0%. This contributed to the annual value of 814.09% for FY2024, which is 287600.0% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' EBIT Margin is 3327.57%, which was down 29504800.0% from 916.75% recorded in Q2 2025.
  • Recursion Pharmaceuticals' EBIT Margin's 5-year high stood at 377.1% during Q3 2024, with a 5-year trough of 4042.41% in Q4 2024.
  • For the 5-year period, Recursion Pharmaceuticals' EBIT Margin averaged around 1292.28%, with its median value being 916.75% (2025).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' EBIT Margin surged by 293818100bps in 2021, and later plummeted by -31340500bps in 2024.
  • Recursion Pharmaceuticals' EBIT Margin (Quarter) stood at 2564.55% in 2021, then soared by 83bps to 445.91% in 2022, then plummeted by -104bps to 908.36% in 2023, then tumbled by -345bps to 4042.41% in 2024, then increased by 18bps to 3327.57% in 2025.
  • Its last three reported values are 3327.57% in Q3 2025, 916.75% for Q2 2025, and 1297.85% during Q1 2025.